Eisai at a Glance

A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan
Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines.

  • Over 75 years of history

  • More than 10,000 employees worldwide

  • ¥ 645.9 billion annual revenue (FY2020)

Eisai’s Global Network

Japan, Americas, China, EMEA, Asia and Latin America
Revenue by Reporting Segment in FY2020:Overseas Revenue Ratio* 59.2%, Japan 35.9%, Americas 22.1%, China 13.2%, EMEA 8.6%, Asia and Latin America 7.1%, OTC and others 3.9%, Other Business 9.3% *Categorized and calculated by major regions based on location of customers.
Number of Employees by Region (As of the end of FY2020), Consolidated Number of Employees 11,237, Japan 4,613, China 2,060, Americas 1,820, Asia and Latin America 1,578, EMEA 1,166
  • More than 40 subsidiaries worldwide

  • 15 Drug Discovery, Research and Development, and Clinical Research Sites

  • 9 Production sites

EWAY Future & Beyond

In “EWAY Future & Beyond”, the first five years starting in FY2021 is “EWAY Future”, while FY2026 onward is “EWAY Beyond”. The perspective will be shifted from that of patients to The People or each consumer. With “empowering The People to realize their fullest life” as the vision, we will promote creating solutions based on scientific evidence in the areas of our expertise: neurology and oncology. Additionally, we will further enhance the hhc process that is based on the hhc philosophy that we have long been implementing. In the hhc process, we obtain an understanding of the anxieties of our customers, and we resolve those anxieties by formulating strategies for their removal. We will keep ourselves close to the lives of The People by enhancing this process. As a result of such efforts, we will aim to evolve the hhc process to “hhceco”, which is a combination of the hhc philosophy and an ecosystem that will support and enable The People to realize their fullest life from the time that they are in good health up to the final moments of their lives.

Eisai’s Therapeutic Areas of Focus :
Neurology and Oncology

Eisai has positioned neurology and oncology as its therapeutic areas of expertise and focus, where there are many diseases for which adequate treatments have yet to be established. 

Neurology:Aim to realize provision of optimal treatment for neurodegenerative disorders (Alzheimer's disease, etc.) based on pathophysiology Oncology:Aim to realize cancer cure by personalized medicine based on cancer evolution and genome information

Corporate Philosophy

We give first thought to patients and their families, and to increasing the benefits health care provides.

Eisai's corporate philosophy reflects our commitment to business activities aiming to increase the benefits to patients, their families, and consumers, who we clearly recognize as the key players in healthcare. This corporate philosophy is summarized by the term
“human health care (hhc)”.

All employees are recommended to spend 1% of
their working hours with patients

hhc human health care

Eisai’s Access to Medicines Initiatives

“Access to Medicines” is about ensuring that medicines and treatments are made available to the communities that need them. Eisai is promoting initiatives for improving access to medicines in developing and emerging countries.

28 countries 
2.02 billion DEC tablets
(As of August 2021)

Eisai is committed to supplying tablets free of charge from its Vizag Plant in India to 250 million people at risk in lymphatic filariasis endemic countries through the World Health Organization until the disease is completely eliminated in these countries.

Social Recognition (as of September 2020)

  • MSCI 2020 Constituent MSCI Japan ESG Select Leaders Index
  • MSCI 2020 Constituent MSCI Japan Empowering Women Index (WIN)
  • FTSE4Good
  • FTSE Blossom Japan
  • Access to Medicine Index